2023
Trends and Outcomes in Cardiac Arrest Among Heart Failure Admissions
Chouairi F, Miller P, Loriaux D, Katz J, Sen S, Ahmad T, Fudim M. Trends and Outcomes in Cardiac Arrest Among Heart Failure Admissions. The American Journal Of Cardiology 2023, 194: 93-101. PMID: 36889986, DOI: 10.1016/j.amjcard.2023.01.012.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseCardiac arrestHospital cardiac arrestHF admissionsHF hospitalizationArtery diseaseHeart failureRenal diseasePrimary HF admissionsHeart failure admissionsHigher inpatient mortalityClinical Modification codesLong-term outcomesNational Inpatient SampleMultivariate logistic regressionHF patientsInpatient mortalityMultivariate adjustmentInpatient SampleFemale genderTenth RevisionHigher oddsLower oddsInternational ClassificationSerious events
2022
Trends In US Heart Failure Hospitalizations: Increased Volume And Patient Diversity With Decreased Total Costs, 2008-2018
Reinhardt S, Clark K, Chouairi F, Miller E, Kay B, Fuery M, Guha A, Ahmad T, Desai N. Trends In US Heart Failure Hospitalizations: Increased Volume And Patient Diversity With Decreased Total Costs, 2008-2018. Journal Of Cardiac Failure 2022, 28: s109-s110. DOI: 10.1016/j.cardfail.2022.03.280.Peer-Reviewed Original ResearchOverall heart failureHeart failureInpatient mortalityDiagnosis codesHospital costsChronic obstructive pulmonary diseaseIntroduction Heart failureHeart failure hospitalizationPeripheral arterial diseaseObstructive pulmonary diseaseCoronary artery diseaseNational Inpatient SampleLength of stayUS healthcare costsComorbid diabetesHF hospitalizationHospitalization volumeFailure hospitalizationHF cohortArtery diseaseEjection fractionMedian agePulmonary diseaseArterial diseaseHispanic patients
2021
Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes Insights From the EMPA-REG OUTCOME Trial
Sharma A, Ofstad AP, Ahmad T, Zinman B, Zwiener I, Fitchett D, Wanner C, George JT, Hantel S, Desai N, Mentz RJ. Patient Phenotypes and SGLT-2 Inhibition in Type 2 Diabetes Insights From the EMPA-REG OUTCOME Trial. JACC Heart Failure 2021, 9: 568-577. PMID: 34325887, DOI: 10.1016/j.jchf.2021.03.003.Peer-Reviewed Original ResearchConceptsCV deathLatent class analysisTreatment effectsNon-coronary artery diseaseEMPA-REG OUTCOME trialAdvanced coronary diseaseEMPA-REG OUTCOMESGLT-2 inhibitionGlomerular filtration rateType 2 diabetesEmpagliflozin 25EMPA-REGCV diseaseCV riskLower eGFRT2D durationOlder patientsOutcome trialsYounger patientsArtery diseaseCoronary diseaseCox regressionFiltration rateCardiovascular diseaseGroup 2
2020
COVID-19 infections and outcomes in a live registry of heart failure patients across an integrated health care system
Caraballo C, McCullough M, Fuery MA, Chouairi F, Keating C, Ravindra NG, Miller PE, Malinis M, Kashyap N, Hsiao A, Wilson FP, Curtis JP, Grant M, Velazquez EJ, Desai NR, Ahmad T. COVID-19 infections and outcomes in a live registry of heart failure patients across an integrated health care system. PLOS ONE 2020, 15: e0238829. PMID: 32997657, PMCID: PMC7526909, DOI: 10.1371/journal.pone.0238829.Peer-Reviewed Original ResearchConceptsHeart failure patientsIntegrated health care systemHeart Failure RegistryHealth care systemFailure patientsCOVID-19 infectionCare systemCOVID-19SARS-CoV-2 infectionReal-time registryRenin-angiotensin blockersRetrospective chart reviewCoronary artery diseaseRisk of deathCOVID-19 testingAngiotensin blockersMultiple comorbiditiesRespiratory failureChart reviewSymptomatic patientsArtery diseaseHeart failureComorbid conditionsPatient mortalityClinical management